Financial reports
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
27 Mar 23
10-K/A
2021 FY
Annual report (amended)
27 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
8-K
Entry into a Material Definitive Agreement
24 Aug 23
8-K
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
8-K
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
8-K
CytomX Therapeutics Reports Full Year 2022 Financial Results
27 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
11 Mar 24
424B3
Prospectus supplement
25 Aug 23
D
$30.00 mm in options, sold $30.00 mm, 4 investors
16 Aug 23
S-3
Shelf registration
15 Aug 23
S-8
Registration of securities for employees
27 Mar 23
424B5
Prospectus supplement for primary offering
4 Mar 22
S-8
Registration of securities for employees
4 Mar 22
S-3/A
Shelf registration (amended)
16 Aug 21
S-3
Shelf registration
5 Aug 21
S-8
Registration of securities for employees
6 May 21
Proxies
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
28 Aug 23
CORRESP
Correspondence with SEC
23 Aug 23
UPLOAD
Letter from SEC
22 Aug 23
CT ORDER
Confidential treatment order
26 Sep 22
CT ORDER
Confidential treatment order
29 Dec 21
EFFECT
Notice of effectiveness
19 Aug 21
CORRESP
Correspondence with SEC
16 Aug 21
UPLOAD
Letter from SEC
12 Aug 21
SEC STAFF
SEC staff action: Order
5 Mar 21
SEC STAFF
SEC staff action: Order
4 Feb 21
Ownership
4
Sean A. McCarthy
28 Mar 24
4
Zhen Su
22 Mar 24
3
Zhen Su
22 Mar 24
4
LLOYD A ROWLAND
21 Mar 24
4
Sean A. McCarthy
21 Mar 24
4
Christopher Ogden
21 Mar 24
4
MARCIA BELVIN
21 Mar 24
4
Jeffrey B Landau
21 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24